There are many applications that are available today that could be brought into the oncology landscape to create a much more patient-centered focus of experiences for those undergoing care, said Susan Dentzer, senior policy fellow at the Duke-Margolis Center for Health Policy.
There are many applications that are available today that could be brought into the oncology landscape to create a much more patient-centered focus of experiences for those undergoing care, said Susan Dentzer, senior policy fellow at Robert J. Margolis Center for Health Policy at Duke University.
Transcript
Based on your session at ACCC 46th Annual Meeting & Cancer Center Business Summit, can you discuss some examples of disruptive innovations within cancer care delivery?
When we think about innovation, in cancer care delivery, or for that matter, innovation going on all across healthcare, we think largely about the possibility of moving care outside of more conventional institutional settings, to more what we could call—distributed settings. So, homes, communities, work sites, etc. We know that's happening across a lot of health care, particularly through telemedicine. The question is how much of that is applicable to the field of cancer care?
You think about cancer care, and you think, well, that mainly involves laying on of hands—you've got to be in an institution to have surgery done, you've got to be in an institution have chemo, etc; but the question is, what about all the other aspects of cancer care that don't involve those things that are laying out of hands? How much of that can happen outside of institutional settings? The answer is quite a lot, quite a lot, but it doesn't tend to happen even though we know that patients would probably be happier when they could be in the community or at home.
We know that there's a lot of need for information that patients need on a regular basis and they need to be exchanging information with their care providers. What symptoms am I having? How am I reacting to my chemotherapy? Do I have emotional needs? Or other social support needs that need to be met to enable me to live my life with cancer. All of those areas really are applicable now for innovations around telehealth around telegenetics, tele-palliative care. There are many applications now that are available today that could be brought into the system really to create a much more patient focused set of experiences for patients.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More